# ATXI (Avenue Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Avenue Therapeutics, Inc. reported $1.40M in revenue and a net loss of $2.79M for the fiscal year ended December 31, 2025, with a -204.9% operating margin.

- Canonical: https://convexityos.com/fundamentals/ATXI
- Markdown: https://convexityos.com/fundamentals/ATXI.md
- SEC CIK: 0001644963
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:13 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001644963&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $1.40M | Dec 31, 2025 |
| Operating Income | FY 2025 | -$2.88M | -204.9% margin |
| Net Income | FY 2025 | -$2.79M | -198.4% net margin |
| Diluted EPS | FY 2025 | -- | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $1.52M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $1.40M | $0 | -- | -- | -- | -- | -- | -- | -- | -- |
| Research & Development | $1.04M | $6.64M | $6.13M | $2.70M | $1.25M | $2.87M | $22.19M | $17.70M | $6.70M | $1.33M |
| Total Operating Expenses | $4.49M | $11.28M | -- | -- | -- | -- | -- | -- | -- | -- |
| **Operating Income** | -$3.08M | -$11.28M | -$14.54M | -$8.04M | -$3.74M | -$5.21M | -$26.27M | -$21.82M | -$11.42M | -$2.38M |
| Interest Income | $121K | $176K | $126K | $20K | $7.0K | $62K | $357K | $93K | $88K | $0 |
| Interest Expense | -- | -- | -- | -- | -- | -- | -- | $0 | $294K | $420K |
| Income Tax Expense | $2.0K | $0 | $0 | $0 | -- | -- | -- | -- | -- | -- |
| **Net Income** | -$2.91M | -$11.65M | -$10.38M | -$3.55M | -$3.73M | -$5.15M | -$25.91M | -$21.55M | -$12.26M | -$3.18M |
| Basic EPS | -$0.93 | -$15.79 | -$73.48 | -$1.63 | -$0.22 | -$0.31 | -$1.65 | -$2.11 | -$1.85 | -$1.11 |
| **Diluted EPS** | -- | -- | -- | -- | -$0.22 | -$0.31 | -$1.65 | -$2.11 | -$1.85 | -$1.11 |
| Basic Shares Outstanding | 3.1M | 1.3M | 141.2K | 2.2M | 1.1M | 16.5M | 15.7M | 10.2M | 6.6M | 2.9M |
| Diluted Shares Outstanding | -- | -- | -- | 2.2M | 1.1M | 16.5M | 15.7M | 10.2M | 6.6M | 2.9M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | -- | -- | $0 | $1.40M | -- | -- |
| Research & Development | $212K | $247K | $200K | $257K | $177K | $192K | $411K | $565K |
| Total Operating Expenses | $704K | $707K | -- | -- | $724K | $1.11M | -- | -- |
| **Operating Income** | -$704K | -$707K | -$714K | -$752K | -$724K | $297K | -$1.91M | -$1.60M |
| Interest Income | $13K | $17K | $18K | $25K | $34K | $31K | $32K | $24K |
| **Net Income** | -$691K | -$690K | -$695K | -$709K | -$683K | $335K | -$1.85M | -$1.54M |
| Basic EPS | -$0.20 | -$0.21 | -$0.21 | -- | -$0.21 | $0.11 | -$0.62 | -- |
| Basic Shares Outstanding | 3.5M | 3.3M | 3.3M | -- | 3.2M | 3.2M | 3.0M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $2.85M | $2.59M | $1.78M | $6.71M | $3.76M | $3.13M | $8.74M | $2.67M | $11.78M | $197K |
| Short-Term Investments | -- | -- | -- | -- | -- | -- | -- | $0 | $10.00M | $0 |
| **Cash & Short-Term Investments** | $2.85M | $2.59M | $1.78M | $6.71M | $3.76M | $3.13M | $8.74M | $2.67M | $21.78M | $197K |
| **Total Current Assets** | -- | -- | -- | -- | $3.96M | $3.25M | -- | -- | -- | -- |
| **Total Non-Current Assets** | -- | -- | -- | -- | $0 | $0 | -- | -- | -- | -- |
| **Total Assets** | $2.93M | $2.67M | $1.85M | $6.84M | $3.96M | $3.25M | $8.91M | $4.53M | $22.17M | $197K |
| Accounts Payable | -- | $155K | $78K | $129K | $304K | $143K | $354K | $3.09M | $1.54M | $334K |
| **Total Current Liabilities** | $1.10M | $816K | $1.20M | $3.58M | $509K | $886K | $2.12M | $5.16M | $2.79M | $6.42M |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.03M |
| **Total Liabilities** | $1.10M | $816K | $1.20M | $3.58M | $509K | $886K | $2.12M | $5.16M | $2.79M | $8.45M |
| Common Stock | $0 | $0 | $3.0K | $0 | $2.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K |
| Retained Earnings | -$105.5M | -$102.6M | -$90.93M | -$80.55M | -$77.00M | -$73.27M | -$68.12M | -$42.21M | -$20.66M | -$8.40M |
| **Total Stockholders' Equity** | $1.83M | $2.80M | $1.58M | $3.90M | $3.45M | $2.36M | $6.80M | -$631K | $19.38M | -$8.25M |
| Total Equity | $1.83M | $1.86M | $654K | $3.27M | $3.45M | $2.36M | $6.80M | -$631K | $19.38M | -$8.25M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $1.52M | $1.94M | $2.42M | $2.85M | $3.71M | $3.33M | $3.50M | $2.59M |
| **Cash & Short-Term Investments** | $1.52M | $1.94M | $2.42M | $2.85M | $3.71M | $3.33M | $3.50M | $2.59M |
| **Total Assets** | $1.53M | $1.98M | $2.47M | $2.93M | $3.73M | $4.16M | $3.59M | $2.67M |
| Accounts Payable | -- | -- | -- | -- | -- | -- | -- | $155K |
| **Total Current Liabilities** | $1.60M | $1.41M | $1.27M | $1.10M | $1.42M | $1.33M | $1.26M | $816K |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $1.60M | $1.41M | $1.27M | $1.10M | $1.42M | $1.33M | $1.26M | $816K |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Retained Earnings | -$107.6M | -$106.9M | -$106.2M | -$105.5M | -$104.8M | -$104.1M | -$104.4M | -$102.6M |
| **Total Stockholders' Equity** | -$75K | $569K | $1.20M | $1.83M | $3.56M | $4.06M | $3.51M | $2.80M |
| Total Equity | -$75K | $569K | $1.20M | $1.83M | $2.30M | $2.83M | $2.33M | $1.86M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$2.95M | -$11.70M | -$10.49M | -$3.60M | -$3.73M | -$5.15M | -$25.91M | -$21.55M | -$12.26M | -$3.18M |
| Stock-Based Compensation | $665K | $1.24M | $906K | $649K | $442K | $710K | $1.84M | $1.54M | $604K | $28K |
| **Operating Cash Flow** | -$1.83M | -$9.03M | -$9.45M | -$7.60M | -$3.75M | -$4.61M | -$26.26M | -$18.22M | -$6.80M | -$1.63M |
| Purchases of Investments | -- | -- | -- | -- | -- | $0 | -$5.00M | $0 | -$10.00M | $0 |
| **Investing Cash Flow** | -- | $0 | -$3.00M | $0 | -- | -$1.00M | $0 | $10.00M | -$10.00M | $0 |
| Common Stock Issued | $2.09M | $1.62M | $0 | -- | $5.04M | $0 | $35.00M | $0 | $37.95M | $0 |
| Share Repurchases | -- | -- | $0 | -$1.10M | -- | -- | -- | -- | -- | -- |
| **Financing Cash Flow** | $2.09M | $9.84M | $7.53M | $10.54M | $4.38M | $0 | $32.33M | -$895K | $28.39M | $1.81M |
| **Net Change in Cash** | $261K | $811K | -$4.92M | $2.94M | $631K | -$5.61M | $6.07M | -$9.11M | -- | -- |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$691K | -$690K | -$695K | -$726K | -$692K | $329K | -$1.86M | -$1.56M |
| Stock-Based Compensation | $47K | $61K | $61K | $142K | $163K | $175K | $185K | $522K |
| **Operating Cash Flow** | -$422K | -$475K | -$438K | -$854K | $383K | -$176K | -$1.19M | -$764K |
| Common Stock Issued | $0 | $0 | $0 | $0 | $0 | $0 | $2.09M | $761K |
| **Financing Cash Flow** | $0 | $0 | $0 | $0 | $0 | $0 | $2.09M | $761K |
| **Net Change in Cash** | -$422K | -$475K | -$438K | -$854K | $383K | -$176K | $908K | -$3.0K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -219.6% | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **Net Profit Margin** | -207.2% | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Return on Equity (ROE) | -158.8% | -416.6% | -655.9% | -91.0% | -108.1% | -218.4% | -381.0% | -- | -63.3% | -- |
| Return on Assets (ROA) | -99.2% | -436.1% | -560.9% | -51.9% | -94.2% | -158.7% | -290.6% | -476.2% | -55.3% | -1612.7% |
| Current Ratio | -- | -- | -- | -- | 7.78x | 3.66x | -- | -- | -- | -- |
| Quick Ratio | 2.60x | 3.18x | 1.49x | 1.87x | 7.39x | 3.53x | 4.13x | 0.52x | 7.81x | 0.03x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -488.0% | -146.2% | -158.8% | -105.3% | -151.2% | -261.1% | -416.6% |
| Return on Assets (ROA) | -182.0% | -140.5% | -71.0% | -99.2% | -100.5% | -147.5% | -255.0% | -436.1% |
| Quick Ratio | 0.95x | 1.38x | 1.90x | 2.60x | 2.61x | 2.50x | 2.77x | 3.18x |
| **Revenue Growth (YoY)** | -- | -100.0% | -- | -- | -- | -- | -- | -- |
| Operating Income Growth (YoY) | -- | -338.0% | -- | -- | -- | -- | -- | -- |
| **Net Income Growth (YoY)** | -- | -306.0% | -- | -- | -- | -- | -- | -341.2% |
| EPS Growth (YoY) | -- | -290.9% | -- | -- | -- | -- | -- | -- |
| Operating Cash Flow Growth (YoY) | -210.2% | -- | -- | -- | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
